Nuvalent, Inc.
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Oct 28, 2026 (1 day)
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Jun 24, 2026 | Bernstein | downgrade | Outperform → Market Perform | — | 52% |
| Jun 10, 2026 | Truist Securities | downgrade | Buy → Hold | — | 54% |
| Jun 10, 2026 | TD Cowen | downgrade | Buy → Hold | — | 54% |
| Jun 10, 2026 | Barclays | downgrade | Overweight → Equal-Weight | — | 53% |
| Jun 10, 2026 | Wedbush | downgrade | Outperform → Neutral | — | 57% |
| Jun 10, 2026 | UBS | downgrade | Buy → Neutral | — | 54% |
| Jun 10, 2026 | Guggenheim | downgrade | Buy → Neutral | — | 52% |
| Jun 9, 2026 | Wells Fargo | downgrade | Overweight → Equal-Weight | — | 54% |
| Jun 9, 2026 | HC Wainwright & Co. | downgrade | Buy → Neutral | — | 44% |
| Jun 9, 2026 | Cantor Fitzgerald | downgrade | Overweight → Neutral | — | 50% |
| Jun 9, 2026 | Wedbush | downgrade | Outperform → Neutral | — | 57% |
| Jun 9, 2026 | LifeSci Capital | downgrade | Outperform → Market Perform | — | 57% |
| May 28, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 57% |
| May 22, 2026 | Bernstein | initiate | — → Outperform | — | 52% |
| Apr 21, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 8, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 57% |
| Mar 30, 2026 | Wells Fargo | initiate | — → Overweight | — | 54% |
| Feb 27, 2026 | Cantor Fitzgerald | maintain | Overweight → Overweight | $140 | 50% |
| Dec 19, 2025 | JP Morgan | maintain | Overweight → Overweight | $145 | 54% |
| Nov 24, 2025 | Truist Securities | initiate | — → Buy | $140 | 54% |
| Nov 18, 2025 | Goldman Sachs | maintain | Buy → Buy | $135 | 54% |
| Nov 18, 2025 | Baird | maintain | Outperform → Outperform | $158 | 55% |
| Nov 18, 2025 | Guggenheim | maintain | Buy → Buy | $155 | 52% |
| Nov 17, 2025 | Stifel | maintain | Buy → Buy | $135 | 53% |
| Nov 17, 2025 | Leerink Partners | maintain | Outperform → Outperform | $149 | 51% |
| Nov 17, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $155 | 44% |
| Nov 12, 2025 | Canaccord Genuity | initiate | — → Buy | $126 | 48% |
| Oct 31, 2025 | Barclays | maintain | Overweight → Overweight | $112 | 53% |
| Oct 31, 2025 | UBS | maintain | Buy → Buy | $132 | 54% |
| Oct 27, 2025 | Piper Sandler | maintain | Overweight → Overweight | $128 | 54% |
| Oct 15, 2025 | Cantor Fitzgerald | initiate | — → Overweight | $135 | 50% |
| Sep 8, 2025 | Wedbush | reiterate | Outperform → Outperform | $115 | 57% |
| Sep 3, 2025 | Raymond James | initiate | — → Outperform | $105 | 53% |
| Aug 19, 2025 | Piper Sandler | initiate | — → Overweight | $112 | 54% |
| Jun 25, 2025 | Baird | maintain | Outperform → Outperform | $112 | 55% |
| Jun 24, 2025 | Leerink Partners | maintain | Outperform → Outperform | $140 | 51% |
| Jun 24, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $130 | 44% |
| Mar 14, 2025 | UBS | upgrade | Neutral → Buy | $100 | 54% |
| Mar 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Jan 17, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $110 | 44% |
| Dec 30, 2024 | HC Wainwright & Co. | initiate | — → Buy | $110 | 44% |
| Nov 13, 2024 | BMO Capital | maintain | Outperform → Outperform | $134 | 53% |
| Oct 24, 2024 | UBS | initiate | — → Neutral | $100 | 54% |
| Oct 4, 2024 | JP Morgan | maintain | Overweight → Overweight | $125 | 54% |
| Sep 16, 2024 | Guggenheim | maintain | Buy → Buy | $105 | 52% |
| Sep 16, 2024 | Wedbush | maintain | Outperform → Outperform | $115 | 57% |
| Sep 16, 2024 | BMO Capital | maintain | Outperform → Outperform | $132 | 53% |
| Sep 16, 2024 | Stifel | maintain | Buy → Buy | $135 | 53% |
| Sep 9, 2024 | Wedbush | reiterate | Outperform → Outperform | $99 | 57% |
| Sep 4, 2024 | JP Morgan | maintain | Overweight → Overweight | $100 | 54% |
No cross-platform signals in the last 90 days
Price targets, earnings estimates, and firm actions for this ticker — updated within the last 24 hours.
Subscribe for Full Access